Background: Prostate cancer is the ninth most common cancer in the world, and is the number one non-skin cancer that affects men in the United States. Prostate cancer occurs when cells of the prostate mutate and begin to multiply inappropriately. These cells may metastasize from the prostate to other parts of the body, especially the bones, lymph nodes, rectum and bladder. Prostate tumors have unique proteins that may be useful as cancer markers during diagnosis and treatment. A few of the proteins that are specific for prostate tumors include å-methylacyl-CoA racemase (AMACR), the hypermethylated form of retinoic acid receptor ∫2 (RAR∫2) and prostate specific antigen (PSA), which is the most reliable clinical tool for diagnosing and monitoring prostate cancer. Prostate mucin antigen (Pma) is expressed only in prostate carcinomas and and cow submaxillary glands. A high molecular weight protein, Pma contains an O-linked oligosaccharide containing N-acetyl galactosamine. It is a glycoprotein with mucin-like features that may prove to be a useful tumor marker.
Description: Rabbit polyclonal to PMA
Immunogen: KLH conjugated synthetic peptide derived from PMA
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 400 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-500;
·Immunocytochemistry: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
